iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/35272686
Targeted therapies for cancer - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar 11;20(1):90.
doi: 10.1186/s12916-022-02287-3.

Targeted therapies for cancer

Zhijun Zhou  1 , Min Li  2
Affiliations
Editorial

Targeted therapies for cancer

Zhijun Zhou et al. BMC Med. .

Abstract

Targeted therapy is the key for improving overall survival while decreasing the undesirable adverse effects of cancer treatment. Patients who received matched targeted therapies showed dramatically improved overall survival (OS) and progression-free survival (PFS) compared to those without matched therapies. However, each patient responds to targeted therapy differently due to their unique genomic profile. The discrepancy of treatment response between clinical trials and real-world clinical practice highlights an unmet need to develop tailored therapies for individual patients. The development of cutting-edge technologies, such as next-generation sequencing, has enabled us to identify more actionable targets. In this special issue of BMC Medicine, a collection of highly translational and clinical oncology papers presented a series of studies on targeted therapies for a variety of cancer types, aiming to bridge the gap between genomic testing and precision medicine and spark innovations on improving the efficacy of targeted therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhao S, Zhang Z, Zhan J, Zhao X, Chen X, Xiao L, Wu K, Ma Y, Li M, Yang Y, et al. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med. 2021;19(1):223. doi: 10.1186/s12916-021-02089-z. - DOI - PMC - PubMed
    1. Zhang Y, Zhang X, Zhang R, Xu Q, Yang H, Lizaso A, Xu C, Liu J, Wang W, Ou SI, et al. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. BMC Med. 2021;19(1):206. doi: 10.1186/s12916-021-02082-6. - DOI - PMC - PubMed
    1. Zou Z, Xing P, Hao X, Wang Y, Song X, Shan L, Zhang C, Liu Z, Ma K, Dong G, et al. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study. BMC Med. 2022;20(1):12. doi: 10.1186/s12916-021-02207-x. - DOI - PMC - PubMed
    1. Ramagopalan S, Leahy TP, Ray J, Wilkinson S, Sammon C, Subbiah V. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Med. 2021;19(1):209. doi: 10.1186/s12916-021-02070-w. - DOI - PMC - PubMed
    1. Zhang Y, Zeng L, Zhang X, Li Y, Liu L, Xu Q, Yang H, Jiang W, Lizaso A, Qiu L, et al. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC. BMC Med. 2021;19(1):245. doi: 10.1186/s12916-021-02118-x. - DOI - PMC - PubMed

Publication types

LinkOut - more resources